Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2026
2025
2024
2023
2022
2021

Mar 28 2026

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Read More +

Feb 22 2026

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

Read More +

Feb 2 2026

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Read More +

Jan 8 2026

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

Read More +

Nov 5 2025

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Read More +

Nov 5 2025

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Read More +

Sep 28 2025

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

Read More +

Aug 5 2025

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

Read More +

May 12 2025

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

Read More +

Apr 25 2025

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Read More +

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Next page
Last page

Displaying 1 - 10 of 54

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2026 - MoonLake Immunotherapeutics

Privacy Policy